Articles


A blood-use protocol program at Loyola University Hospital in Chicago has lowered the amount of blood products transfused per patient, which in turn has led to greater patient safety and lowered costs, according to research presented at the College of American Pathologists annual meeting in Chicago.
Read More

Removing payment for health insurance deductibles leads to increased, although modest, improvements in the rates of screening for conditions such as cancer and elevated cholesterol (Meeker D, et al. Health Serv Res. 2010. Online doi:10.1111/j.1475-6773.2010.01188.x).
Read More

A study comparing the use of computed tomography (CT) versus standard chest x-rays for screening those at high risk for lung cancer found that CT screening resulted in 20% fewer deaths from the disease.
Read More

Spending money on colorectal cancer screening programs that target the pre-Medicare population (those between 50 and 64 years of age) is necessary to reduce the costs of colorectal cancer in the Medicare program, according to research presented at the American College of Gastroenterology’s 75th Annual Scientific Meeting in San Antonio, TX.
Read More

Paclitaxel (Taxol), which is produced from the bark of the yew, may become cheaper and easier to produce now that researchers have isolated and grown stem cells from that tree (Nat Biotechnol.
Read More

The United Kingdom’s (UK) Department of Health has pledged £250 million toward a Cancer Drugs Fund that will pay for new treatments not available in the state-funded health system.
Read More


This study compared the safety and efficacy of a new regimen—bortezomib plus dexamethasone and vincristine— compared with vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (VAD) in previously untreated multiple myeloma (MM) (J Clin Oncol. 2010;28:4621-4629).
Read More

A discussion of new drug development using the example of acute myeloid leukemia (AML)—but that is applicable to a broad range of diseases— outlines the problems inherent in phase 2 clinical trials that may lead to falsepositive results, and how trial design can be improved and drug development be made more efficient and less costly (Blood. 2010;116:2420-2428).
Read More

Page 319 of 329